Latest news

Debiopharm Group™ s’engage auprès du TELETHON avec un partenariat de soutien

Debiopharm Group™ Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450, its Potent Anti-staphylococcal Agent

Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada

Presented by the Japanese Cancer Association and Debiopharm Group™, the ‘JCA-Mauvernay Award 2014’ goes to Doctors Hara and Shibata

Debiopharm Diagnostics portfolio company Biocartis ships its first Idylla instrument

Debiopharm Group™’s innovative antibiotic Debio 1450 – developed from its proprietary plateform Fabiotics – Receives Qualified Infectious Disease Product (QIDP)…

Debiopharm Group™ and Nobelex Biotech start two collaborations on development of new antibiotics against N. gonorrhoeae and enteric species

Debiopharm Group™ and TCG Lifesciences Ltd. announce successful completion of first phase of research collaboration on discovery of novel antibiotics

Debiopharm Group™ Announces Initiation of a Phase I Study of Debio 1450, an IV/oral Potent Antibiotic Active Against Staphylococcal Infections